# Neuronax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuronax

- Industry: Pharmaceuticals
- Headquarters: France
- Website: www.neuronax.com
- Total disclosed funding: $4.5M
- Latest round: Series D (May 4, 2019)
- Investors on record: 3

## About

Neuronax is a domain services company that specializes in acquiring and managing premium domain names, offering branding solutions tailored for startups and businesses.Neuronax operates in the domain services sector, focusing on facilitating the acquisition of premium domain names. Founded in France, the company's headquarters is located in Paris. It has undergone strategic pivots to enhance its service offerings. The founder has a history of experience in tech entrepreneurship, although specific previous ventures aren't detailed. Neuronax has secured a total of EUR 1.5 million in Series D funding in May 2019, raising the total amount raised to EUR 1.5 million, with a current company valuation of EUR 3.455 million. This round was backed by investors including FaDiese, Simba Santé, and Sofimac Partners.Neuronax offers a comprehensive suite of services focused on premium domain acquisition, including the sale of distinctive, brandable domains, especially one-word names under modern extensions such as .ai, .io, and .xyz. Their services extend to domain transfer assistance, trademark validation and filing, alongside branding resources like logo design and naming contests. The target clientele includes entrepreneurs and businesses in technology, neuroscience, and biotechnology, serving a global market that spans North America, Europe, Asia, and beyond.Neuronax generates revenue through direct domain sales and associated value-added services. Client transactions primarily involve one-time purchases of domain names, with supplementary income stemming from trademark services and branding consultations. The pricing model typically includes a flat fee for domain purchases and potential annual renewal fees for registrations, designed to facilitate immediate acquisition and ongoing brand development through optional services like trademark filing.Following its EUR 1.5 million Series D funding in May 2019, Neuronax plans to invest in the development of new product offerings and expand into additional geographical markets. Specific markets targeted for expansion have not been disclosed, but the funding will be allocated to implementing growth strategies and enhancing service capabilities to further support their clients.

## Funding rounds

- Series D, May 4, 2019, $1.7M — Sofimac Partners, FaDiese, Simba Santé
- Series C, Nov 28, 2017, $2.8M — Sofimac Partners, FaDiese, Simba Santé

## Investors

- Sofimac Partners (https://capitalatlas.ai/funds/sofimac-partners) — Series C, Series D
- FaDiese (https://capitalatlas.ai/funds/fadiese) — Series C, Series D
- Simba Santé — Series C, Series D